Patents Assigned to Janssen Pharmaceutica
-
Publication number: 20230419850Abstract: Cognitive and mood states of a real world person are assessed according to activity in a virtual world environment with which the person interacts. The virtual world is configured to provide interactive experiences for assessing the person's cognitive and/or mood states. The system requires configuration of a session avatar during each virtual world session to provide then-current insight into the person's mood state. The system may require configuration of an avatar reflective of the person's state. The system requires the person to configure the virtual world environment during each virtual session to provide then-current insight into the person's mood state. The system permits the user to visit destinations, perform tasks and play games that are included in the environment for the purpose of providing insight into the person's cognitive and/or mood states according to the person's selections and/or performance.Type: ApplicationFiled: March 27, 2023Publication date: December 28, 2023Applicant: Janssen Pharmaceutica NVInventors: Joseph Barbuto, Katherine Bettencourt, Carine Brouillon, Gabriel Brun, Alexandra Kramer, Joe Manfredonia, Husseini Manji, Kenneth Mosca, Mark Sapp, Magdalena Schoeneich
-
Patent number: 11856084Abstract: Embodiments facilitate interoperability and secure determination of healthcare costs. An entity may receive a first Electronic Health Record (EHR) sub-block with patient medical coverage information and first treatments and may transmit a first Device Drug Information (DIR) sub-block comprising first treatment classes corresponding to each first treatment, first treatment class members corresponding to each first treatment class, and corresponding first treatment class member cost information. In response, the entity may receive a second EHR sub-block comprising second treatments each: associated with a corresponding first treatment, and selected from corresponding first treatment class members. Upon receipt of a transaction confirmation, the entity may augment a multi-dimensional blockchain with a multi-dimensional block formed by linking: a DIR block including second treatment information, an EHR block including information based on the second EHR sub-block and a transaction block.Type: GrantFiled: December 15, 2022Date of Patent: December 26, 2023Assignee: Janssen Pharmaceutica NVInventors: Jessica Lee, Jun Morimura, Michael Moschetti, John Vig, Marvin Quesada, Andrew Thomson
-
Patent number: 11848080Abstract: Embodiments facilitate interoperability and secure patient selection for clinical trials and drug/device deployments. An entity may obtain a first set of health parameters and collective demographic information associated with one or more population segments and receive Electronic Health Record (EHR) sub-blocks with patient profile information and corresponding patient medical histories for patients. The entity may determine a subset of eligible candidate patients for a treatment based on information in the EHR sub-blocks and eligibility criteria for the treatment, which may be based the first set of health parameters, and/or the collective demographic information.Type: GrantFiled: December 15, 2022Date of Patent: December 19, 2023Assignee: Janssen Pharmaceutica NVInventors: Jessica Lee, Jun Morimura, Michael Moschetti, John Vig, Marvin Quesada, Andrew Thomson
-
Patent number: 11845748Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: March 17, 2022Date of Patent: December 19, 2023Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
-
Patent number: 11839663Abstract: The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.Type: GrantFiled: September 29, 2020Date of Patent: December 12, 2023Assignee: Janssen Pharmaceutica NVInventors: Gang Chen, Chaofeng Huang, Jimmy T. Liang
-
Patent number: 11827634Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.Type: GrantFiled: December 13, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceutica NVInventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
-
Patent number: 11827638Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.Type: GrantFiled: March 16, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceutica NVInventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
-
Patent number: 11819502Abstract: The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage.Type: GrantFiled: June 6, 2022Date of Patent: November 21, 2023Assignee: Janssen Pharmaceutica NVInventors: Sabine Karine Katrien Inghelbrecht, Jakob Andreas Beirowski, Henning Gieseler
-
Patent number: 11820766Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: GrantFiled: December 23, 2020Date of Patent: November 21, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Patent number: 11819476Abstract: The present invention provides compounds of formula I, compositions thereof, and methods of using the same as mTORC1 inhibitors.Type: GrantFiled: December 4, 2020Date of Patent: November 21, 2023Assignee: Janssen Pharmaceutica NVInventors: David John O'Neill, Eddine Saiah, Seong Woo Anthony Kang
-
Patent number: 11820770Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.Type: GrantFiled: January 14, 2022Date of Patent: November 21, 2023Assignee: JANSSEN PHARMACEUTICA NVInventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
-
Patent number: 11814364Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: March 17, 2022Date of Patent: November 14, 2023Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
-
Patent number: 11802111Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.Type: GrantFiled: September 21, 2021Date of Patent: October 31, 2023Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant
-
Publication number: 20230338341Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.Type: ApplicationFiled: June 29, 2023Publication date: October 26, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
-
Patent number: 11787798Abstract: Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.Type: GrantFiled: March 25, 2021Date of Patent: October 17, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Cynthia B. Berry, Krisztián Biró, Pablo Garcia-Reynaga, Andrew V. Samant, Warren S. Wade
-
Patent number: 11787807Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.Type: GrantFiled: July 15, 2021Date of Patent: October 17, 2023Assignee: Janssen Pharmaceutica NVInventors: Philippe Fernandes, Paul J. Krawczuk, Mark S. Tichenor
-
Publication number: 20230301573Abstract: The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. The disclosed methods use monitoring of a subset of symptoms and/or one or more biomarkers. The symptom severity can be assessed using the Positive and Negative Syndrome Scale (PANSS) parameters. The methods of the invention can be used to provide early intervention to decrease or prevent relapse in schizophrenia patients.Type: ApplicationFiled: May 9, 2023Publication date: September 28, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: Dai Wang, Srihari Gopal, Vaibhav Narayan, Adam Savitz, Susan Baker
-
Patent number: 11767354Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.Type: GrantFiled: February 5, 2021Date of Patent: September 26, 2023Assignee: Janssen Pharmaceutica NVInventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
-
Patent number: 11759455Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.Type: GrantFiled: September 14, 2021Date of Patent: September 19, 2023Assignee: JANSSEN PHARMACEUTICA NVInventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
-
Patent number: D1007675Type: GrantFiled: August 27, 2021Date of Patent: December 12, 2023Assignee: Janssen Pharmaceutica NVInventors: James Glencross, Will Davies, Ian Scrimgeour